Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 31;26(1):443–458. doi: 10.1080/10717544.2019.1574935

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — PEIPOS efficacy against MDR ovarian cancer cells and siRNA complexation of surface-modified PEIPOS liposomal formulations. (a) P-gp characterization of the A2780 and A2780-ADR cells using fluorescently-labeled P-gp antibody. The mean fluorescence intensity (MFI) was normalized by isotype control. n = 3, mean ± SD. (b) Cytotoxicity of noncoated and coated PEIPOS formulations on A2780-ADR P-gp overexpressing human ovarian cancer cell line following 4 + 44h treatment scheme in serum-complete media. Data shown indicate triplicate mean ± SD from blinded experiment. *p < .05, ***p < .0005, ****p < .0001, two-way ANOVA with Tukey’s multiple comparisons test. (c) Ethidium bromide stained agarose gel electrophoresis of free siRNA and its complexes with 0.5%PEIPOS at different N/P ratios. (d) P-gp downregulation on A2780-ADR cells after treatment with 0.5%PEIPOS formulation with an N/P 13 ratio. The downregulated protein determination was carried out at the end of 48h incubation following 4h of treatment in serum-complete media. n = 3 independent trials, mean ± SD.